Cargando…

Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials

BACKGROUND: The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and would also respond to the therapeutic intervention. OBJECTIVE: To investigate if predictive models can be an effective tool for identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezzati, Ali, Davatzikos, Christos, Wolk, David A., Hall, Charles B., Habeck, Christian, Lipton, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919041/ https://www.ncbi.nlm.nih.gov/pubmed/35310531 http://dx.doi.org/10.1002/trc2.12223

Ejemplares similares

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Delayed-start analysis for demonstrating disease modification of solanezumab
por: Wolters, Frank J., et al.
Publicado: (2015)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging
por: Lou, Carolyn, et al.
Publicado: (2021)

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease
por: Hassan, Mubashir, et al.
Publicado: (2018)

Association of Intensive vs Standard Blood Pressure Control With Regional Changes in Cerebral Small Vessel Disease Biomarkers: Post Hoc Secondary Analysis of the SPRINT MIND Randomized Clinical Trial
por: Rashid, Tanweer, et al.
Publicado: (2023)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Post hoc power analysis: is it an informative and meaningful analysis?
por: Zhang, Yiran, et al.
Publicado: (2019)

Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
por: Thaçi, Diamant, et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration
por: Kandel, Benjamin M., et al.
Publicado: (2016)

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
por: Lin, Yi, et al.
Publicado: (2023)

Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials
por: Fulcher, Greg, et al.
Publicado: (2018)

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data
por: Archer, David F., et al.
Publicado: (2017)

Effects of treatment with eluxadoline on abdominal pain in patients with IBS‐D: Additional post hoc analyses of Phase 3 trials
por: Lembo, Anthony J., et al.
Publicado: (2020)

Comparison between midazolam and propofol in acute phase for ventilated patients with sepsis: a post‐hoc analysis of the DESIRE trial
por: Miyagawa, Noriko, et al.
Publicado: (2022)

Efficacy of remimazolam versus midazolam for procedural sedation: post hoc integrated analyses of three phase 3 clinical trials
por: Dao, Van-Anh, et al.
Publicado: (2022)

Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
por: Conaghan, Philip G, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
por: Tesser, John, et al.
Publicado: (2023)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Balanced resuscitation and earlier mortality end points: bayesian post hoc analysis of the PROPPR trial
por: Lammers, Daniel, et al.
Publicado: (2023)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

Post hoc depression analysis from a pharmacist-led diabetes trial
por: Bateman, M. Thomas, et al.
Publicado: (2023)

Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation
por: Kario, Kazuomi, et al.
Publicado: (2023)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Post-hoc power analysis: a conceptually valid approach for power based on observed study data
por: Quach, Natalie E, et al.
Publicado: (2022)

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
por: Gallo, Silvina, et al.
Publicado: (2020)

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
por: Lemiere, Catherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sc4udlfbu9jb1befstguug2cgv